Interleukin-1β up-regulates the expression of thrombopoietin and transcription factors c-Jun c-Fos, GATA-1, and NF-E2 in megakaryocytic cells

Journal of Laboratory and Clinical Medicine

Volumn 143, Issue 2, 2004, Pages 75-88

  Chuen, Carmen Ka Yee ^a   Li, Karen ^a   Yang, Mo ^a   Fok, Tai Fai ^a   Li, Chi Kong ^a   Chui, Cecilia Mei Yan ^a   Yuen, Patrick Man Pan ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; MESSENGER RNA; PROTEIN C FOS; PROTEIN C JUN; THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; DNA BINDING PROTEIN; ERYTHROID SPECIFIC DNA BINDING FACTOR; GATA1 PROTEIN, HUMAN; INTERLEUKIN 1; NFE2 PROTEIN, HUMAN; PRIMER DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MEGAKARYOCYTE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; UPREGULATION; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; KINETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; SOUTHERN BLOTTING;

BASE SEQUENCE; BLOTTING, SOUTHERN; CELL LINE; CYCLOHEXIMIDE; DACTINOMYCIN; DNA PRIMERS; DNA-BINDING PROTEINS; ERYTHROID-SPECIFIC DNA-BINDING FACTORS; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1; KINETICS; MEGAKARYOCYTES; NF-E2 TRANSCRIPTION FACTOR; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; THROMBOPOIETIN; TRANSCRIPTION FACTORS;

EID: 1242294510     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2003.09.006     Document Type: Article

References (43)

1. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991;77:1627-52.
2. Bankers-Fulbright JL, Kalli KR, McKean DJ. Interteukin-1 signal transduction. Life Sci 1996;59:61-83.
3. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
4. Dalmau SR, Freitas CS, Tabak DG. Interleukin-1 and tumor necrosis factor-alpha as radio- and chemo-protectors of bone marrow. Bone Marrow Transplant 1993;12:551-63.
5. Neta R, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells. J Immunol 1994;153:1536-44.
6. Nakai S, Hirai Y. The therapeutic potential of interleukin-1 beta in the treatment of chemotherapy- or radiation-induced myelosuppression and in tumor therapy. Biotherapy 1989;1:339-54.
7. Kimura H, Ishibashi T, Shikama Y, Okano A, Akiyama Y, Uchida T, et al. Interleukin-1β (IL-1β) induces thrombocytosis in mice: possible implication of IL-6. Blood 1990;76:2493-500.
8. Monroy RL, Davis TA, Donahue RE, MacVittie TJ. In vivo stimulation of platelet production in a primate model using IL-1 and IL-3. Exp Hematol 1991;19:629-35.
9. Dan K, Gomi S, Inokuchi K, Ogata K, Yamada T, Ohki I, et al. Effects of Interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 1995;93:67-72.
10. Briddell RA, Hoffman R. Cytokine regulation of the human burst-forming unit-megakaryocyte. Blood 1990:76:516-22.
11. Williams JL, Pipia GG, Datta NS, Long MW. Thrombopoietin requires additional megakaryocyte-active cytokines for optimal ex vivo expansion of megakaryocyte precursor cells. Blood 1998;91:4118-26.
12. Van den Oudenrijn S, De Haas M, Calafat J, Van der Schoot CE, Von dem Borne AE. A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes. Br J Haematol 1999;106:553-63.
13. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophy Acta 1991;1072:129-57.
14. Karin M, Liu ZG, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-6.
15. Mouthon MA, Navarro S, Katz A, Breton-Gorius J, Vainchenker W. c-jun and c-fos are expressed by human megakaryocytes. Exp Hematol 1992;20:909-15.
16. Weiss MJ, Orkin SH. GATA transcription factors: key regulators of hematopoiesis. Exp Hematol 1995;23:99-107.
17. Lemarchandel V, Ghysdael J, Mignotte V, Rahuel C, Romeo PH. GATA and Ets cis-acting sequences mediate megakaryocyte-specific expression. Mol Cell Biol 1993;13:668-76.
18. Minami T, Tachibana K, Imanishi T, Doi T. Both Ets-1 and GATA-1 are essential for positive regulation of platelet factor 4 gene expression. Eur J Biochem 1998;258:879-89.
19. Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH, Mignotte V. Analysis of the thrombopoietin receptor (MPL) promoter implicates GATA and Ets proteins in the coregulation of megakaryocyte-specific genes. Blood 1996;87:4678-85.
20. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J 1997;16:3965-73.
21. Takahashi S, Komeno T, Suwabe N, Yoh K, Nakajima O, Nishimura S, et al. Role of GATA-1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. Blood 1998;92:434-42.
22. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 1999;93:2867-75.
23. Shivdasani RA, Orkin SH. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc Natl Acad Sci U S A 1995;92:8690-4.
24. Levin J, Peng JP, Baker GR, Villeval JL, Lecine P, Burstein SA, et al. Pathophysiology of thrombocytopenia and anemia in mice lacking transcription factor NF-E2. Blood 1999;94:3037-47.
25. Yang M, Li K, Chui CMY, Yuen PMP, Chan PK, Chuen CKY, et al. Expression of interleukin (IL) 1 type I and type II receptors in megakaryocytic cells and enhancing effects of IL-1β on megakaryocytopoiesis and NF-E2 expression. Br J Haematol 2000;111:371-80.
26. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, Nagura H, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 1985;66:1384-92.
27. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
28. Chui CMY, Li K, Yang M, Chuen CKY, Fok TF, Li CK, et al. Platelet-derived growth factor up-regulates the expression of transcription factors NF-E2, GATA-1 and c-Fos in megakaryocytic cell lines. Cytokine 2003;21:51-64.
29. Castell D, Suhasini M, Gudi T, Naima R, Pilz RB. Regulation of the erythroid transcription factor NF-E2 by cyclic adenosine monophosphate- dependent protein kinase. Blood 1998;9:3193-201.
30. Carter DB, Deibel MR Jr, Dunn CJ, Tomich CS, Laborde AL, Slightom JL, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-8.
31. Granowitz EV, Clark BD, Mancilla J, Dinarello CA. Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991;266:14147-50.
32. Gershenwald JE, Fong Y, Fahey TJ, Calvano SE, Chizzonite R, Kilian PL, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci U S A 1990;87:4966-70.
33. Granowitz EV, Clark BD, Vannier E, Callahan MV, Dinarello CA. Effect of interleukin-1 (IL-1) blockade on cytokine synthesis. I. IL-1 receptor antagonist inhibits IL-1-induced cytokine synthesis and blocks the binding of IL-1 to its type II receptor on human monocytes. Blood 1992;79:2356-63.
34. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, et al. Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 1991;78:1915-8.
35. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 2002;100:3479-83.
36. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
37. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-31.
38. Solar GP, Kerr WG, Zeigler FC, Hess D, Donahue C, de Sauvage FJ, et al. Role of c-mpl in early hematopoiesis. Blood 1998;92:4-10.
39. Drachman JG, Sabath DF, Fox NE, Kaushansky K. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 1997;89:483-92.
40. Wendling F, Vainchenker W. Thrombopoietin and its receptor. Eur Cytokine Netw 1998;9:221-31.
41. Nagata Y, Nagahisa H, Aida Y, Okutomi K, Nagasawa T, Todokoro K. Thrombopoietin induces megakaryocyte differentiation in hematopoietic progenitor FDC-P2 cells. J Biol Chem 1995;270:19673-5.
42. Matsumura I, Kanakura Y, Kalo T, Ikeda H, Horikawa Y, Ishikawa J, et al. The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood 1996;88:3074-82.
43. Ezumi Y, Nishida E, Uchiyama T, Takayama H. Thrombopoietin potentiates agonist-stimulated activation of p38 mitogen-activated protein kinase in human platelets. Biochem Biophys Res Commun 1999;261:58-63.